The University of Cambridge Department of Haematology is located at the Cambridge Biomedical Campus and the Wellcome Trust Genome Campus. It has laboratories in the Jeffrey Cheah Biomedical Centre, the Cambridge Institute for Medical Research, NHS Blood and Transplant Blood Centre and the Wellcome Sanger Institute. The Head of Department is Professor Brian Huntly.
The department has four main goals:
- To conduct internationally competitive biomedical research.
- To provide education in medical aspects of haematology to undergraduate scientists and medical students.
- To provide postgraduate education, largely through the provision of PhD students.
- To contribute to the clinical activities of the Addenbrooke's Department of Haematology.
Recent publications
Unique molecular and functional features of extramedullary hematopoietic stem and progenitor cell reservoirs in humans. Blood. 2022 Jun 9;139(23):3387-3401.
Analysis of single-cell RNA sequencing data based on autoencoders. BMC Bioinformatics. 2021 Jun 8;22(1):309.
p57Kip2 regulates embryonic blood stem cells by controlling sympathoadrenal progenitor expansion. Blood. 2022 Jun 2:blood.2021014853.
Whole-exome sequencing identifies rare genetic variants associated with human plasma metabolites. Am J Hum Genet. 2022 Jun 2;109(6):1038-1054.
Leukemia. 2022 Jun;36(6):1585-1595.
The longitudinal dynamics and natural history of clonal haematopoiesis. Nature. 2022 Jun;606(7913):335-342.
Clonal dynamics of haematopoiesis across the human lifespan. Nature. 2022 Jun;606(7913):343-350
The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells. Leukemia. 2022 May 26.
Crystal structures of BMPRII extracellular domain in binary and ternary receptor complexes with BMP10. Nat Commun. 2022 May 3;13(1):2395.
Hemasphere. 2022 Apr 29;6(5):e0714
Npm1 Haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice. Blood Adv. 2022 Apr 25:bloodadvances.2022007015.
Immune disease variants modulate gene expression in regulatory CD4+ T cells. Cell Genom. 2022 Apr 13;2(4)
Sci Adv. 2022 Apr 8;8(14):eabm2094.
TET2 regulates immune tolerance in chronically activated mast cells. JCI Insight. 2022 Apr 8;7(7):e154191.
Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature. 2022 Apr 8.
A cholinergic neuroskeletal interface promotes bone formation during postnatal growth and exercise. Cell Stem Cell. 2022 Apr 7;29(4):528-544.e9.
Bayesian networks elucidate complex genomic landscapes in cancer. Commun Biol. 2022 Apr 4;5(1):306.
Valet C, Magnen M, Qiu L, Cleary SJ, Wang KM, Ranucci S, Grockowiak E, Boudra R, Conrad C, Seo Y, Calabrese DR, Greenland JR, Leavitt AD, Passegué E, Méndez-Ferrer S, Swirski FK, Looney MR. Sepsis promotes splenic production of a protective platelet pool with high CD40 ligand expression. J Clin Invest. 2022 Apr 1;132(7):e153920.
Molecular subclusters of follicular lymphoma: a report from the UK's Haematological Malignancy Research Network. Blood Adv. 2022 Apr 1:bloodadvances.2021005284.
The NIHR BioResource is a panel of volunteers, with and without health conditions, who will participate in research studies investigating the links between genes, the environment, health and disease enabling scientific discoveries as well as facilitating translational medicine for the benefit of patients.They donate their DNA via a blood or saliva sample which is used together with other information, such as gender, ethnicity, lifestyle and health information to match them to specific research studies. The NIHR Cambridge Centre is one of 13 centres which make up the NIHR BioResource.
Cambridge Blood and Stem Cell BioBank
The Cambridge Blood and Stem Cell Biobank is a tissue bank for samples from patients with haematological malignancies and normal individuals, including cord blood. We are also the repository for the UK Myeloproliferative Disorders (MPD) sample bank, and several clinical trials for this group of disorders. The bank has collected over 15,000 blood and bone marrow-derived samples to date from patients with haematological malignancies and approximately 2600 normal individuals, all curated in a bespoke database designed to facilitate research activities. Existing samples and prospective collections are available to researchers working on ethically approved studies in malignant blood disorders and normal blood development, and 4800 samples have been transferred to researchers both in the UK and internationally.